12:00 AM
 | 
Oct 25, 1999
 |  BC Week In Review  |  Clinical News  |  Regulatory

Ergoset bromocriptine regulatory update

ERGO received a letter from the FDA stating that its NDA for Ergoset to treat Type II diabetes is approvable but that ERGO must address the agency's concerns regarding clinical safety as well as...

Read the full 147 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >